We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Long-term Follow-up and Final Height in Girls With Central Precocious Puberty Treated With Luteinizing Hormone—Releasing Hormone Analogue Nasal Spray

Emanuele Cacciari, MD; Alessandra Cassio, MD; Antonio Balsamo, MD; Cristina Colli, MD; Alessandro Cicognani, MD; Piero Pirazzoli, MD; Giovanni Tani, MD; Lorena Brondelli, MD; Marina Mandini, PhD; Luciano Bovicelli, MD
Arch Pediatr Adolesc Med. 1994;148(11):1194-1199. doi:10.1001/archpedi.1994.02170110080014.
Text Size: A A A
Published online


Objective:  To evaluate clinical, hormonal, and auxologic features in a group of girls with central precocious puberty during and after long-term treatment with luteinizing hormone—releasing hormone analogue nasal spray.

Design:  Clinical survey, before-after trial.

Setting:  Pediatric Clinic, Endocrinological Center, University of Bologna (Italy).

Patients:  Forty-one girls with central precocious puberty were treated for 28 months (range, 12 to 60 months); 25 of them discontinued therapy at a mean chronological age of 10.0±0.9 years and were followed up for 25 months (range, 6 to 50 months). Twelve patients achieved adult height.

Intervention:  Buserelinacetate (D-Ser [TBU] LHRH Al-9EA) nasal spray; 1800 μg/d subdivided into six intranasal administrations of 300 μg each.

Measurements/Main Results:  Basal follicle-stimulating hormone, peak gonadotropin values (fluoro-immunoenzymatic method, Eurogenetics, Tessenderlo, Belgium; sensitivity was 0.5 IU/L for luteinizing hormone and 1IU/L for follicle-stimulating hormone), and estradiol (radioimmunoassay method, DPC Kit, Los Angeles, Calif; sensitivity was 11.01 pmol/L were significantly suppressed (P<.0001) as of the third month of treatment and increased significantly (P<.01) to pretreatment levels 6 months after discontinuation of therapy. Uterine and mean ovarian volumes, which were stable throughout treatment, appeared significantly higher (P<.05) than before treatment at only 6 months after stopping therapy. In patients with more advanced bone age (according to Greulich and Pyle) at onset of treatment, we observed a more significant improvement of SD score for height (Tanner). Mean adult height in our patients was 159.5±6.1 cm, and the variables that were significantly associated with final height were height age/bone age ratio at onset and target height (according to Tanner).

Conclusions:  Long-term buserelin treatment administered nasally is effective because of completeness of inhibition, quick reversibility after treatment is stopped, and lack of side effects. Its auxologic results are different depending on bone age advancement at onset, which represents a predictor of "therapeutic success." Further follow-up would be useful.(Arch Pediatr Adolesc Med. 1994;148:1194-1199)


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.